Kunwei Shen

15PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Genome structure and regulationPredictive and prognostic markersMolecular targetsMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 04, 2026
Reply to: Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection.

|Jan 13, 2026
Decoding adipocyte heterogeneity through single-nucleus transcriptomics unveils subtype-specific adipocytes orchestrate immunosuppressive niches in breast cancer.

Yiwei Tong, Zheng Wang, Niu Qiao

|Dec 09, 2025
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.

Xiaosong Chen, Jiahui Huang, Haoting Shi

|May 21, 2024
The 21-Gene Recurrence Score Assay Improved Multidisciplinary Treatment Compliance in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: An Analysis of 2,323 Patients.

Liangqiang Li, Jing Yu, Kunwei Shen

|Aug 21, 2023
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.

Siji Zhu, Yujie Lu, Xiaochun Fei

|Sep 20, 2022
TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2.

Cixiang Zhou, Difei Wang, Jingchi Li

Pageof 3

Frequent Collaborators

6 joint publications

Xiaosong Chen

6 joint publications

Xiaosong Chen

2 joint publications

Jing Yu

2 joint publications

Haoting Shi